


How similar is this cluster to the other clusters?

Genes in the cluster along with the pathways as annotated by experts


Expert Annotation		
Treatment	Pathway	Regulation Type
RHOA_Q63L	Canonical Cytoskeletal Re-org	Activator
PRKACA_WT.1	Canonical PKA	Activator
PRKACA_WT.2	Canonical PKA	Activator
GLI1_WT	Hedgehog	Activator




Top 5 genes negatively correlated to the cluster

Expert Annotation			Mean Correlation	Standard Deviation
Treatment	Pathway	Regulation Type		
CSNK1A1.WT.3	Canonical WNT	Inhibitor	-0.54	0.07
RPS6KB1.WT.1	Canonical TOR	Activator	-0.54	0.10
AKT1.WT.1	Canonical PI3K/AKT	Activator	-0.50	0.08
STK11.WT.2	Canonical TOR	Inhibitor	-0.49	0.09
MAPKAP1.WT	Canonical TOR	Activator	-0.49	0.15


What groups of morphological features are distinguishing in the cluster relative to the untreated samples? (maximum of absolute m-score for the features belonging to the same category; m-score defined as median of a feature z-score across genes in the cluster) Black means no feature is available in the category



Which individual morphological features are distinguishing in the cluster relative to the untreated samples? Blue/Red means the feature has a positive/negative z-score. Size is proportional to the z-score value.



How strongly are genes within the cluster correlated?



Empty

Plate : 41744 - Genes in the Cluster (Channels are sorted based on their dominance in the grid plot)






GLI1.WT

PRKACA.WT.1






PRKACA.WT.2

RHOA.Q63L

DNA




ER



Compound IDs and common names (where available); blue/red colored box means the matching compound is positively/negatively correlated with the cluster	Chemical structure	Mean pairwise replicates correlation of the compound signature (95th DMSO replicate correlation is 0.54)	Mean $\pm$ standard deviation correlation between compound and each gene in cluster; Tables contain data for individual genes	Mean compound rank when scored against genes in cluster using L1000 profiling $\pm$ standard deviation; Tables contain data for individual genes	How similar is the compound signature to the gene clusters in this experiment? (Yellow and red lines correspond to top/bottom 1st and 5th percentile DMSO correlation to all the genes)	Common distinguishing feature categories in the compound and genes in the cluster relative to the untreated samples	Distinguishing individual features for the compound relative to untreated samples. Black means a mismatch; i.e. active (= high z-score in magnitude) in the compound, and either inactive (= small z-score in magnitude) or oppositely active in the gene cluster	Number of PubChem assays in which the compound was tested; assays in which the compound was active are itemized
BRD-K92570288-001-01-7 PubChem CID : 54614939		0.91 (in 4 replicates)	$0.76 \pm 0.04$ Treatment   Score GLI1.WT   0.97 PRKACA.WT.1   0.90 PRKACA.WT.2   0.78 RHOA.Q63L   0.91	$0.910 \pm 0.038$ Treatment   Score GLI1.WT   0.936 PRKACA.WT.1   0.867 PRKACA.WT.2   0.960 RHOA.Q63L   0.870				Total number of assays tested in: 19.
BRD-K86981519-001-01-5 PubChem CID : 44496872		0.90 (in 4 replicates)	$0.72 \pm 0.04$ Treatment   Score GLI1.WT   0.93 PRKACA.WT.1   0.871 PRKACA.WT.2   0.77 RHOA.Q63L   0.69	$0.656 \pm 0.339$ Treatment   Score GLI1.WT   0.832 PRKACA.WT.1   0.871 PRKACA.WT.2   0.763 RHOA.Q63L   0.837				Total number of assays tested in: 29.






BRD-K52251545-001-05-2  
AC1M5VPS  
MLS000418615  
HMS2531C16  
ZINC3270008  
SMR000247565  
T0510-7581  
PubChem CID : 2386323



0.83 (in 4 replicates)

0.71 ± 0.05  
Treatment Score  
GLUT-WT 1.03  
PRKACA-WT1 0.93  
PRKACA-WT2 0.76  
RHOA-Q68L 1.02


NA



Total number of assays tested in: 629. Active in the following assays:

- Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 (AID 1479)
- Antagonist of Human D 1 Dopamine Receptor: qHTS (AID 504652)
- High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set (AID 588497)




BRD-A61437901-001-06-4  
AC1MELUG  
MLS001034555  
HMS2964O04  
STK056804  
SMR000664698  
ST50589848  
PubChem CID : 2905407



0.93 (in 2 replicates)

0.67 ± 0.06  
Treatment Score  
GLUT-WT 0.90  
PRKACA-WT1 0.80  
PRKACA-WT2 0.82  
RHOA-Q68L 0.71


NA



Total number of assays tested in: 505. Active in the following assays:

- Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7). (AID 1861)
- Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication (AID 1885)
- Fluorescence-based confirmation cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7). (AID 1952)
- Luminescence Cell-Based/Microorganism Dose Confirmation HTS to Identify Inhibitors of T.Cruzi Replication. (AID 2044)
- Fluorescence-based counterscreen for antagonists of the G-protein coupled receptor 7 (GPR7): cell-based high throughput screening assay to identify antagonists of the melanin-concentrating hormone receptor 1 (MCHR1). (AID 2148)
- Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR). (AID 2435)
- Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R) (AID 2797)
- Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors (AID 504326)
- Antagonist of Human D 1 Dopamine Receptor: qHTS (AID 504652)
- Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS (AID 504660)
- Primary qHTS for delayed death inhibitors of the malarial parasite plasmodium, 48 hour incubation (AID 504832)
- Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1) (AID 588814)
- Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHO1K1 cell line (AID 602248)
- Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5) (AID 624037)
- Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4) (AID 624127)
- Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1) (AID 624466)
- Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1) (AID 624467)
- qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT (AID 686979)
- qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS (AID 720551)
- qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS (AID 720553)
- qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS (AID 720579)




BRD-K20428666-003-06-2  
MLS000672046  
SMR000293477  
AC1MHCD3  
PubChem CID : 2949708



NA (in 1 replicates)

0.65 ± 0.04  
Treatment Score  
GLUT-WT 0.69  
PRKACA-WT1 0.63  
PRKACA-WT2 0.66  
RHOA-Q68L 0.60





















NA





Total number of assays tested in: 616. Active in the following assays:

- qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1) (AID 1030)
- Leishmania major promastigote HTS (AID 1063)
- qHTS Assay for Inhibitors of Bacillus subtilis Sp phosphotransferase (PPTase) (AID 1490)
- Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype (AID 1531)
- Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7). (AID 1861)
- Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication (AID 1885)
- High Throughput Screen of 100,000 compound library to Identify Inhibitors of Mycobacterium tuberculosis H37Rv (AID 1949)
- Fluorescence-based confirmation cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7). (AID 1952)
- Fluorescence-based counterscreen for antagonists of the G-protein coupled receptor 7 (GPR7): cell-based high throughput screening assay to identify antagonists of the melanin-concentrating hormone receptor 1 (MCHR1). (AID 2148)
- VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity (AID 2546)
- HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists (AID 485344)
- Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MCHR (AID 540308)
- HTS Assay for Peg3 Promoter Inhibitors (AID 588405)
- mHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay (AID 602440)
- Dose response confirmation of mHTS inhibitor hits of the mitochondrial permeability transition pore via an absorbance assay (AID 651561)
- Dose response confirmation of mHTS inhibitor hits of the mitochondrial permeability transition pore via a fluorescent based counterscreen assay (AID 651564)
- Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library (AID 651702)
- qHTS Assay for Inhibitors of Hepatitis C Virus (HCV) (AID 651820)
- Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with compounds from Cherry Pick01 (AID 651954)
- qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line (AID 686870)
- qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line (AID 686971)
- qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT (AID 686978)
- qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT (AID 686979)
- qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen (AID 743279)















BRD-K91098396-001-01-9 PubChem CID : 54619176		0.79 (in 4 replicates)	<div><div>0.64 ± 0.03</div><table><tr><td>Treatment</td><td>Score</td></tr><tr><td>GLI1-WT</td><td>0.66</td></tr><tr><td>PRKACA-WT1</td><td>0.02</td></tr><tr><td>PRKACA-WT2</td><td>0.60</td></tr><tr><td>RHOA-Q68L</td><td>0.06</td></tr></table></div> <div><div>0.213 ± 0.343</div><table><tr><td>Treatment</td><td>Score</td></tr><tr><td>GLI1-WT</td><td>0.227</td></tr><tr><td>PRKACA-WT1</td><td>0.042</td></tr><tr><td>PRKACA-WT2</td><td>0.035</td></tr><tr><td>RHOA-Q68L</td><td>0.047</td></tr></table></div>	Treatment	Score	GLI1-WT	0.66	PRKACA-WT1	0.02	PRKACA-WT2	0.60	RHOA-Q68L	0.06	Treatment	Score	GLI1-WT	0.227	PRKACA-WT1	0.042	PRKACA-WT2	0.035	RHOA-Q68L	0.047				Total number of assays tested in: 37.
Treatment	Score																										
GLI1-WT	0.66																										
PRKACA-WT1	0.02																										
PRKACA-WT2	0.60																										
RHOA-Q68L	0.06																										
Treatment	Score																										
GLI1-WT	0.227																										
PRKACA-WT1	0.042																										
PRKACA-WT2	0.035																										
RHOA-Q68L	0.047																										
BRD-K27496085-001-06-9 MLS000762893 SMR000439717 AC1LXW72 BDBM58089 HMS2785113 HMS3469C13 ZINC8657900 STK848802 ZINC08657900 ST50782147 T6363733 F3348-0380 PubChem CID : 1838594		NA (in 1 replicates)	<div><div>0.63 ± 0.05</div><table><tr><td>Treatment</td><td>Score</td></tr><tr><td>GLI1-WT</td><td>0.07</td></tr><tr><td>PRKACA-WT1</td><td>0.01</td></tr><tr><td>PRKACA-WT2</td><td>0.27</td></tr><tr><td>RHOA-Q68L</td><td>0.07</td></tr></table></div> <div>NA</div>	Treatment	Score	GLI1-WT	0.07	PRKACA-WT1	0.01	PRKACA-WT2	0.27	RHOA-Q68L	0.07				Total number of assays tested in: 569. Active in the following assays: <ul style="list-style-type: none"><li>HTS to identify inhibitors of αVAD Induced Cell Death in L929 Cells. (AID 1377)</li><li>High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv (AID 1626)</li><li>MLPCN Streptokinase Expression Inhibition (AID 1662)</li><li>Luminescence Microorganism-Based Dose Confirmation HTS to Identify Compounds Cytotoxic to SK(-)GAS Group A Streptococcus (AID 1900)</li><li>Luminescence Microorganism-Based Dose Confirmation HTS to Identify Inhibitors of Streptokinase Promotor Activity (AID 1902)</li><li>Luminescence Microorganism-Based Dose Response HTS to Identify Compounds Cytotoxic to Streptococcus (AID 1915)</li><li>qHTS for inhibitors of ROR gamma transcriptional activity (AID 2551)</li><li>Primary qHTS for delayed death inhibitors of the malarial parasite plasid, 48 hour incubation (AID 504832)</li><li>αHTS identification of small molecule Triacylglycerol inhibitors in a fluorescence assay (AID 651582)</li><li>Single concentration confirmation of small molecule Triacylglycerol inhibitors in a fluorescence assay (AID 651629)</li><li>qHTS of TDP-43 Inhibitors (AID 652104)</li><li>qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT (AID 686978)</li></ul>										
Treatment	Score																										
GLI1-WT	0.07																										
PRKACA-WT1	0.01																										
PRKACA-WT2	0.27																										
RHOA-Q68L	0.07																										
BRD-K28901743-001-05-3 ZINC01748812 AC1LTAWC MLS000552933 ZINC1748812 CCG-15676 STL331422 BAS 00558059 SMR000175471 ST50181975 PubChem CID : 1555494		NA (in 1 replicates)	<div><div>0.62 ± 0.06</div><table><tr><td>Treatment</td><td>Score</td></tr><tr><td>GLI1-WT</td><td>0.04</td></tr><tr><td>PRKACA-WT1</td><td>0.06</td></tr><tr><td>PRKACA-WT2</td><td>0.56</td></tr><tr><td>RHOA-Q68L</td><td>0.70</td></tr></table></div> <div>NA</div>	Treatment	Score	GLI1-WT	0.04	PRKACA-WT1	0.06	PRKACA-WT2	0.56	RHOA-Q68L	0.70				Total number of assays tested in: 626. Active in the following assays: <ul style="list-style-type: none"><li>Screen for Chemicals that Extend Yeast Lifespan (AID 775)</li><li>αHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay (AID 463190)</li><li>Single concentration confirmation of small molecule inhibitors of tim10-1 yeast via a luminescent assay (AID 463213)</li><li>Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis (AID 588726)</li><li>Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen (AID 652039)</li><li>Fluorescence Intensity-based biochemical primary high throughput confirmation assay to identify activators of kallikrein-7 (K7) zymogen (AID 680949)</li><li>Counterscreen for activators of kallikrein-7 (K7) zymogen: Fluorescence intensity-based biochemical high throughput counterscreen assay for activators that optically interfere with measurement of EDANS-DABCYL fluorescence (AID 686952)</li></ul>										
Treatment	Score																										
GLI1-WT	0.04																										
PRKACA-WT1	0.06																										
PRKACA-WT2	0.56																										
RHOA-Q68L	0.70																										
BRD-K25144184-001-07-5 MLS000703473 SMR000322926 F0440-0373 ZINC04078730 AC1NASUU BDBM69090 HMS2685M05 ZINC4078730 PubChem CID : 4432160		0.65 (in 2 replicates)	<div><div>0.62 ± 0.05</div><table><tr><td>Treatment</td><td>Score</td></tr><tr><td>GLI1-WT</td><td>0.02</td></tr><tr><td>PRKACA-WT1</td><td>0.56</td></tr><tr><td>PRKACA-WT2</td><td>0.02</td></tr><tr><td>RHOA-Q68L</td><td>0.09</td></tr></table></div> <div>NA</div>	Treatment	Score	GLI1-WT	0.02	PRKACA-WT1	0.56	PRKACA-WT2	0.02	RHOA-Q68L	0.09				Total number of assays tested in: 640. Active in the following assays: <ul style="list-style-type: none"><li>Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90) (AID 1789)</li><li>Aqueous Solubility from MLSMR Stock Solutions (AID 1996)</li><li>Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity (AID 2097)</li><li>Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha (AID 2650)</li><li>Luminescence Cell-Free Homogeneous Dose Retest to Identify Inhibitors of Glycogen Synthase Kinase-3 beta Activity (AID 434954)</li><li>Inhibition of Human GSK-3 beta Activity Measured in Biochemical System Using Microfluidics - 2063-05.Inhibitor.Dose.DryPowder.Activity.Set2 (AID 588429)</li><li>Inhibition of Human CDK5 Activity Measured in Biochemical System Using Microfluidics - 2063-07.Inhibitor.Dose.DryPowder.Activity (AID 588430)</li><li>Inhibition of Human GSK-3 alpha Activity Measured in Biochemical System Using Microfluidics - 2063-06.Inhibitor.Dose.DryPowder.Activity.Set2 (AID 588434)</li><li>Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3) (AID 651719)</li><li>Fluorescence-based cell-based primary high throughput confirmation assay to identify antagonists of the Galanin Receptor 3 (GalR3) (AID 652245)</li><li>Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01.Activator.SinglePoint.HTS.Activity (AID 743287)</li></ul>										
Treatment	Score																										
GLI1-WT	0.02																										
PRKACA-WT1	0.56																										
PRKACA-WT2	0.02																										
RHOA-Q68L	0.09																										
BRD-K86600397-001-01-8 PubChem CID : 44501134		0.86 (in 4 replicates)	<div><div>0.61 ± 0.05</div><table><tr><td>Treatment</td><td>Score</td></tr><tr><td>GLI1-WT</td><td>0.66</td></tr><tr><td>PRKACA-WT1</td><td>0.02</td></tr><tr><td>PRKACA-WT2</td><td>0.03</td></tr><tr><td>RHOA-Q68L</td><td>0.03</td></tr></table></div> <div><div>0.846 ± 0.125</div><table><tr><td>Treatment</td><td>Score</td></tr><tr><td>GLI1-WT</td><td>0.208</td></tr><tr><td>PRKACA-WT1</td><td>0.007</td></tr><tr><td>PRKACA-WT2</td><td>0.065</td></tr><tr><td>RHOA-Q68L</td><td>0.095</td></tr></table></div>	Treatment	Score	GLI1-WT	0.66	PRKACA-WT1	0.02	PRKACA-WT2	0.03	RHOA-Q68L	0.03	Treatment	Score	GLI1-WT	0.208	PRKACA-WT1	0.007	PRKACA-WT2	0.065	RHOA-Q68L	0.095				Total number of assays tested in: 33.
Treatment	Score																										
GLI1-WT	0.66																										
PRKACA-WT1	0.02																										
PRKACA-WT2	0.03																										
RHOA-Q68L	0.03																										
Treatment	Score																										
GLI1-WT	0.208																										
PRKACA-WT1	0.007																										
PRKACA-WT2	0.065																										
RHOA-Q68L	0.095																										



BRD-K00659699-001-05-3 MLS000392966 SMR000248123 T5227208 AC1MSJKL MLS002634504 BDBM68072 HMS2547C15 ZINC9631316 ZINC09631316 PubChem CID : 3560290		NA (in 1 replicates)	<table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI.WT</td><td>-0.75</td></tr><tr><td>PRKACA.WT.1</td><td>-0.65</td></tr><tr><td>PRKACA.WT.2</td><td>-0.45</td></tr><tr><td>RHOA.Q6L</td><td>-0.72</td></tr></table> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI.WT</td><td>-0.69 ± 0.05</td></tr></table>	Treatment	Score	GLI.WT	-0.75	PRKACA.WT.1	-0.65	PRKACA.WT.2	-0.45	RHOA.Q6L	-0.72	Treatment	Score	GLI.WT	-0.69 ± 0.05	NA				<ul style="list-style-type: none"><li>Total number of assays tested in: 618. Active in the following assays:</li><li>Screen for Chemicals that Inhibit the RAM Network (AID 868)</li><li>Leishmania major promastigote HTS (AID 1063)</li><li>Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Confirmatory Screen (AID 1361)</li><li>Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen (AID 1362)</li><li>MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators (AID 1814)</li><li>High Content Assay for Compounds that inhibit the Assembly of the Perinuclear Compartment (AID 2417)</li><li>qHTS for inhibitors of ROR gamma transcriptional activity (AID 2551)</li><li>HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress (AID 2732)</li><li>Assay for HTS of Gi/Go-linked GPCRs using mGluR8: Primary Screening (AID 488969)</li><li>CHOP Confirmatory Screen (AID 504437)</li><li>Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A) (AID 58511)</li><li>uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay (AID 602449)</li><li>Activators of the GIRK family of Potassium Channels (GIRK Confirmatory-CRC) (AID 623909)</li><li>Activators of the GIRK family of Potassium Channels (GIRK1/2 Confirmatory) (AID 623911)</li><li>Single concentration confirmation of uHTS inhibitor hits of the mitochondrial permeability transition pore via a fluorescent based assay (AID 624504)</li><li>qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line (AID 686971)</li><li>qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT (AID 686979)</li></ul>											
Treatment	Score																																
GLI.WT	-0.75																																
PRKACA.WT.1	-0.65																																
PRKACA.WT.2	-0.45																																
RHOA.Q6L	-0.72																																
Treatment	Score																																
GLI.WT	-0.69 ± 0.05																																
BRD-K96634415-001-01-3 PubChem CID : 54646028		NA (in 1 replicates)	<table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI.WT</td><td>-0.69</td></tr><tr><td>PRKACA.WT.1</td><td>-0.45</td></tr><tr><td>PRKACA.WT.2</td><td>-0.67</td></tr><tr><td>RHOA.Q6L</td><td>-0.70</td></tr></table> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI.WT</td><td>-0.68 ± 0.02</td></tr></table> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI.WT</td><td>0.730 ± 0.085</td></tr><tr><td>PRKACA.WT.1</td><td>0.743</td></tr><tr><td>PRKACA.WT.2</td><td>0.762</td></tr><tr><td>RHOA.Q6L</td><td>0.697</td></tr></table>	Treatment	Score	GLI.WT	-0.69	PRKACA.WT.1	-0.45	PRKACA.WT.2	-0.67	RHOA.Q6L	-0.70	Treatment	Score	GLI.WT	-0.68 ± 0.02	Treatment	Score	GLI.WT	0.730 ± 0.085	PRKACA.WT.1	0.743	PRKACA.WT.2	0.762	RHOA.Q6L	0.697				Total number of assays tested in: 38.		
Treatment	Score																																
GLI.WT	-0.69																																
PRKACA.WT.1	-0.45																																
PRKACA.WT.2	-0.67																																
RHOA.Q6L	-0.70																																
Treatment	Score																																
GLI.WT	-0.68 ± 0.02																																
Treatment	Score																																
GLI.WT	0.730 ± 0.085																																
PRKACA.WT.1	0.743																																
PRKACA.WT.2	0.762																																
RHOA.Q6L	0.697																																
BRD-K88686946-001-01-1 PubChem CID : 54646013		NA (in 1 replicates)	<table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI.WT</td><td>-0.76</td></tr><tr><td>PRKACA.WT.1</td><td>-0.65</td></tr><tr><td>PRKACA.WT.2</td><td>-0.43</td></tr><tr><td>RHOA.Q6L</td><td>-0.67</td></tr></table> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI.WT</td><td>-0.68 ± 0.05</td></tr></table> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI.WT</td><td>0.519 ± 0.230</td></tr><tr><td>PRKACA.WT.1</td><td>0.373</td></tr><tr><td>PRKACA.WT.2</td><td>0.379</td></tr><tr><td>PRKACA.WT.2</td><td>0.756</td></tr><tr><td>RHOA.Q6L</td><td>0.668</td></tr></table>	Treatment	Score	GLI.WT	-0.76	PRKACA.WT.1	-0.65	PRKACA.WT.2	-0.43	RHOA.Q6L	-0.67	Treatment	Score	GLI.WT	-0.68 ± 0.05	Treatment	Score	GLI.WT	0.519 ± 0.230	PRKACA.WT.1	0.373	PRKACA.WT.2	0.379	PRKACA.WT.2	0.756	RHOA.Q6L	0.668				Total number of assays tested in: 40.
Treatment	Score																																
GLI.WT	-0.76																																
PRKACA.WT.1	-0.65																																
PRKACA.WT.2	-0.43																																
RHOA.Q6L	-0.67																																
Treatment	Score																																
GLI.WT	-0.68 ± 0.05																																
Treatment	Score																																
GLI.WT	0.519 ± 0.230																																
PRKACA.WT.1	0.373																																
PRKACA.WT.2	0.379																																
PRKACA.WT.2	0.756																																
RHOA.Q6L	0.668																																
BRD-K58469266-001-01-0 PubChem CID : 54646063		NA (in 1 replicates)	<table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI.WT</td><td>-0.65</td></tr><tr><td>PRKACA.WT.1</td><td>-0.64</td></tr><tr><td>PRKACA.WT.2</td><td>-0.66</td></tr><tr><td>RHOA.Q6L</td><td>-0.71</td></tr></table> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI.WT</td><td>-0.67 ± 0.03</td></tr></table> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI.WT</td><td>0.557 ± 0.192</td></tr><tr><td>PRKACA.WT.1</td><td>0.379</td></tr><tr><td>PRKACA.WT.2</td><td>0.411</td></tr><tr><td>RHOA.Q6L</td><td>0.668</td></tr></table>	Treatment	Score	GLI.WT	-0.65	PRKACA.WT.1	-0.64	PRKACA.WT.2	-0.66	RHOA.Q6L	-0.71	Treatment	Score	GLI.WT	-0.67 ± 0.03	Treatment	Score	GLI.WT	0.557 ± 0.192	PRKACA.WT.1	0.379	PRKACA.WT.2	0.411	RHOA.Q6L	0.668				Total number of assays tested in: 39.		
Treatment	Score																																
GLI.WT	-0.65																																
PRKACA.WT.1	-0.64																																
PRKACA.WT.2	-0.66																																
RHOA.Q6L	-0.71																																
Treatment	Score																																
GLI.WT	-0.67 ± 0.03																																
Treatment	Score																																
GLI.WT	0.557 ± 0.192																																
PRKACA.WT.1	0.379																																
PRKACA.WT.2	0.411																																
RHOA.Q6L	0.668																																
BRD-K59420052-001-05-1 ST50277656 ZINC00318938 AC1LFSO4 MLS000677351 HMS2648M19 ZINC318938 CCG-15022 BAS 05338703 SMR000286104 PubChem CID : 808203		NA (in 1 replicates)	<table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI.WT</td><td>-0.72</td></tr><tr><td>PRKACA.WT.1</td><td>-0.62</td></tr><tr><td>PRKACA.WT.2</td><td>-0.65</td></tr><tr><td>RHOA.Q6L</td><td>-0.69</td></tr></table> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI.WT</td><td>-0.67 ± 0.04</td></tr></table>	Treatment	Score	GLI.WT	-0.72	PRKACA.WT.1	-0.62	PRKACA.WT.2	-0.65	RHOA.Q6L	-0.69	Treatment	Score	GLI.WT	-0.67 ± 0.04	NA				<ul style="list-style-type: none"><li>Total number of assays tested in: 636. Active in the following assays:</li><li>MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators (AID 1814)</li><li>Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin (AID 2314)</li><li>A qHTS for Small Molecule Inhibitors of Shiga Toxin (AID 2315)</li><li>Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR) (AID 2796)</li><li>qHTS Assay for NPC1 Promoter Activators (AID 485313)</li><li>qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project) (AID 588342)</li><li>Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1) (AID 624467)</li><li>Fluorescence-based cell-based primary high throughput confirmation assay to identify agonists of the human trace amine associated receptor 1 (TAAR1) (AID 651783)</li><li>Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12). (AID 687014)</li><li>qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen (AID 720504)</li><li>qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen (AID 743279)</li><li>Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01 Activator.SinglePoint.HTS.Activity (AID 743398)</li></ul>											
Treatment	Score																																
GLI.WT	-0.72																																
PRKACA.WT.1	-0.62																																
PRKACA.WT.2	-0.65																																
RHOA.Q6L	-0.69																																
Treatment	Score																																
GLI.WT	-0.67 ± 0.04																																
BRD-K76407984-001-01-9 PubChem CID : 54641072		NA (in 1 replicates)	<table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI.WT</td><td>-0.68</td></tr><tr><td>PRKACA.WT.1</td><td>-0.59</td></tr><tr><td>PRKACA.WT.2</td><td>-0.47</td></tr><tr><td>RHOA.Q6L</td><td>-0.72</td></tr></table> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>GLI.WT</td><td>-0.66 ± 0.05</td></tr></table>	Treatment	Score	GLI.WT	-0.68	PRKACA.WT.1	-0.59	PRKACA.WT.2	-0.47	RHOA.Q6L	-0.72	Treatment	Score	GLI.WT	-0.66 ± 0.05	NA				Total number of assays tested in: 38.											
Treatment	Score																																
GLI.WT	-0.68																																
PRKACA.WT.1	-0.59																																
PRKACA.WT.2	-0.47																																
RHOA.Q6L	-0.72																																
Treatment	Score																																
GLI.WT	-0.66 ± 0.05																																



BRD-K61437861-001-01-1 PubChem CID : 54646478		0.75 (in 3 replicates)	<div><div>-0.66 ± 0.04</div><table><tr><td>Treatment</td><td>Score</td></tr><tr><td>GLI1.WT</td><td>-0.66</td></tr><tr><td>PRKACA.WT.1</td><td>-0.61</td></tr><tr><td>PRKACA.WT.2</td><td>-0.68</td></tr><tr><td>HR23A.Q58L</td><td>-0.69</td></tr></table></div> <div><div>0.441 ± 0.265</div><table><tr><td>Treatment</td><td>Score</td></tr><tr><td>GLI1.WT</td><td>0.469</td></tr><tr><td>PRKACA.WT.1</td><td>0.379</td></tr><tr><td>PRKACA.WT.2</td><td>0.178</td></tr><tr><td>HR23A.Q58L</td><td>0.306</td></tr></table></div>	Treatment	Score	GLI1.WT	-0.66	PRKACA.WT.1	-0.61	PRKACA.WT.2	-0.68	HR23A.Q58L	-0.69	Treatment	Score	GLI1.WT	0.469	PRKACA.WT.1	0.379	PRKACA.WT.2	0.178	HR23A.Q58L	0.306			<div>Cytoplasm_Intensity_MitotensityEdge_AGP Nuclei_Texture_Surveillance_AGP_3.0 Cytoplasm_Intensity_MitotensityEdge_ER</div> <div>Cells_Intensity_UpperQuartIntensity_DNA Cells_Intensity_MedianIntensity_RNA Cells_Intensity_LowerQuartIntensity_RNA</div> <div>Nuclei_Intensity_IntegratedIntensityEdge_ER Cytoplasm_Intensity_IntegratedIntensityEdge_RNA Nuclei_Intensity_IntegratedIntensity_AGP Nuclei_Intensity_IntegratedIntensity_ER</div> <div>Nuclei_AreaShape_Zernike_3.1 Cytoplasm_AreaShape_Zernike_3.1 Cytoplasm_AreaShape_Zernike_7.1 Cells_Intensity_Zernike_0.9 Cytoplasm_AreaShape_Zernike_4.2</div>	Total number of assays tested in: 36.
Treatment	Score																										
GLI1.WT	-0.66																										
PRKACA.WT.1	-0.61																										
PRKACA.WT.2	-0.68																										
HR23A.Q58L	-0.69																										
Treatment	Score																										
GLI1.WT	0.469																										
PRKACA.WT.1	0.379																										
PRKACA.WT.2	0.178																										
HR23A.Q58L	0.306																										
BRD-K42959654-001-01-9 PubChem CID : 54646040		NA (in 1 replicates)	<div><div>-0.66 ± 0.04</div><table><tr><td>Treatment</td><td>Score</td></tr><tr><td>GLI1.WT</td><td>-0.64</td></tr><tr><td>PRKACA.WT.1</td><td>-0.61</td></tr><tr><td>PRKACA.WT.2</td><td>-0.69</td></tr><tr><td>HR23A.Q58L</td><td>-0.70</td></tr></table></div> <div><div>0.198 ± 0.155</div><table><tr><td>Treatment</td><td>Score</td></tr><tr><td>GLI1.WT</td><td>0.209</td></tr><tr><td>PRKACA.WT.1</td><td>0.379</td></tr><tr><td>PRKACA.WT.2</td><td>0.084</td></tr><tr><td>HR23A.Q58L</td><td>0.051</td></tr></table></div>	Treatment	Score	GLI1.WT	-0.64	PRKACA.WT.1	-0.61	PRKACA.WT.2	-0.69	HR23A.Q58L	-0.70	Treatment	Score	GLI1.WT	0.209	PRKACA.WT.1	0.379	PRKACA.WT.2	0.084	HR23A.Q58L	0.051			<div>Cytoplasm_Intensity_MitotensityEdge_AGP Nuclei_Texture_Surveillance_AGP_3.0 Cytoplasm_Intensity_MitotensityEdge_ER</div> <div>Cells_RadialDistribution_RadialCY_ER_1st Cells_Intensity_UpperQuartIntensity_DNA Cells_Intensity_MedianIntensity_RNA Cells_Intensity_LowerQuartIntensity_RNA</div> <div>Cells_Intensity_IntegratedIntensity_ER Cytoplasm_Intensity_IntegratedIntensityEdge_RNA Nuclei_Intensity_IntegratedIntensity_ER Nuclei_Texture_Surveillance_DNA_3.0 Nuclei_Texture_Surveillance_Mito_3.0</div> <div>Nuclei_AreaShape_Zernike_4.5 Cells_Intensity_Zernike_0.9 Nuclei_Texture_IntegratedIntensity_Mito_3.0 Cells_Texture_IntegratedIntensity_DNA_3.0</div>	Total number of assays tested in: 42.
Treatment	Score																										
GLI1.WT	-0.64																										
PRKACA.WT.1	-0.61																										
PRKACA.WT.2	-0.69																										
HR23A.Q58L	-0.70																										
Treatment	Score																										
GLI1.WT	0.209																										
PRKACA.WT.1	0.379																										
PRKACA.WT.2	0.084																										
HR23A.Q58L	0.051																										
BRD-K69123433-001-05-9 SMR000131239 MLS000520830 AC1MMIMY MLS002588601 HMS2421D24 ZINC2976551 PubChem CID : 3261615		NA (in 1 replicates)	<div><div>-0.66 ± 0.04</div><table><tr><td>Treatment</td><td>Score</td></tr><tr><td>GLI1.WT</td><td>-0.71</td></tr><tr><td>PRKACA.WT.1</td><td>-0.65</td></tr><tr><td>PRKACA.WT.2</td><td>-0.62</td></tr><tr><td>HR23A.Q58L</td><td>-0.68</td></tr></table></div> <div><div>NA</div><table><tr><td>Treatment</td><td>Score</td></tr><tr><td>GLI1.WT</td><td>0.147</td></tr><tr><td>PRKACA.WT.1</td><td>0.050</td></tr><tr><td>PRKACA.WT.2</td><td>0.054</td></tr><tr><td>HR23A.Q58L</td><td>0.085</td></tr></table></div>	Treatment	Score	GLI1.WT	-0.71	PRKACA.WT.1	-0.65	PRKACA.WT.2	-0.62	HR23A.Q58L	-0.68	Treatment	Score	GLI1.WT	0.147	PRKACA.WT.1	0.050	PRKACA.WT.2	0.054	HR23A.Q58L	0.085			<div>Cytoplasm_Intensity_MitotensityEdge_ER</div> <div>Cells_Intensity_UpperQuartIntensity_DNA Cells_Intensity_MedianIntensity_ER Cells_Intensity_LowerQuartIntensity_RNA Cells_Intensity_IntegratedIntensity_ER</div> <div>Cells_Intensity_IntegratedIntensityEdge_RNA Nuclei_Texture_Surveillance_AGP_3.0 Cytoplasm_Intensity_UpperQuartIntensity_ER</div> <div>Cells_Intensity_Zernike_0.9 Cells_Intensity_Zernike_3.0 Cells_Intensity_Zernike_4.5 Cells_Intensity_Zernike_5.0 Cells_Intensity_Zernike_6.0 Cells_Intensity_Zernike_7.0 Cells_Intensity_Zernike_8.0 Cells_Intensity_Zernike_9.0 Cells_Intensity_Zernike_10.0 Cells_Intensity_Zernike_11.0 Cells_Intensity_Zernike_12.0 Cells_Intensity_Zernike_13.0 Cells_Intensity_Zernike_14.0 Cells_Intensity_Zernike_15.0 Cells_Intensity_Zernike_16.0 Cells_Intensity_Zernike_17.0 Cells_Intensity_Zernike_18.0 Cells_Intensity_Zernike_19.0 Cells_Intensity_Zernike_20.0 Cells_Intensity_Zernike_21.0 Cells_Intensity_Zernike_22.0 Cells_Intensity_Zernike_23.0 Cells_Intensity_Zernike_24.0 Cells_Intensity_Zernike_25.0 Cells_Intensity_Zernike_26.0 Cells_Intensity_Zernike_27.0 Cells_Intensity_Zernike_28.0 Cells_Intensity_Zernike_29.0 Cells_Intensity_Zernike_30.0 Cells_Intensity_Zernike_31.0 Cells_Intensity_Zernike_32.0 Cells_Intensity_Zernike_33.0 Cells_Intensity_Zernike_34.0 Cells_Intensity_Zernike_35.0 Cells_Intensity_Zernike_36.0 Cells_Intensity_Zernike_37.0 Cells_Intensity_Zernike_38.0 Cells_Intensity_Zernike_39.0 Cells_Intensity_Zernike_40.0 Cells_Intensity_Zernike_41.0 Cells_Intensity_Zernike_42.0 Cells_Intensity_Zernike_43.0 Cells_Intensity_Zernike_44.0 Cells_Intensity_Zernike_45.0 Cells_Intensity_Zernike_46.0 Cells_Intensity_Zernike_47.0 Cells_Intensity_Zernike_48.0 Cells_Intensity_Zernike_49.0 Cells_Intensity_Zernike_50.0 Cells_Intensity_Zernike_51.0 Cells_Intensity_Zernike_52.0 Cells_Intensity_Zernike_53.0 Cells_Intensity_Zernike_54.0 Cells_Intensity_Zernike_55.0 Cells_Intensity_Zernike_56.0 Cells_Intensity_Zernike_57.0 Cells_Intensity_Zernike_58.0 Cells_Intensity_Zernike_59.0 Cells_Intensity_Zernike_60.0 Cells_Intensity_Zernike_61.0 Cells_Intensity_Zernike_62.0 Cells_Intensity_Zernike_63.0 Cells_Intensity_Zernike_64.0 Cells_Intensity_Zernike_65.0 Cells_Intensity_Zernike_66.0 Cells_Intensity_Zernike_67.0 Cells_Intensity_Zernike_68.0 Cells_Intensity_Zernike_69.0 Cells_Intensity_Zernike_70.0 Cells_Intensity_Zernike_71.0 Cells_Intensity_Zernike_72.0 Cells_Intensity_Zernike_73.0 Cells_Intensity_Zernike_74.0 Cells_Intensity_Zernike_75.0 Cells_Intensity_Zernike_76.0 Cells_Intensity_Zernike_77.0 Cells_Intensity_Zernike_78.0 Cells_Intensity_Zernike_79.0 Cells_Intensity_Zernike_80.0 Cells_Intensity_Zernike_81.0 Cells_Intensity_Zernike_82.0 Cells_Intensity_Zernike_83.0 Cells_Intensity_Zernike_84.0 Cells_Intensity_Zernike_85.0 Cells_Intensity_Zernike_86.0 Cells_Intensity_Zernike_87.0 Cells_Intensity_Zernike_88.0 Cells_Intensity_Zernike_89.0 Cells_Intensity_Zernike_90.0 Cells_Intensity_Zernike_91.0 Cells_Intensity_Zernike_92.0 Cells_Intensity_Zernike_93.0 Cells_Intensity_Zernike_94.0 Cells_Intensity_Zernike_95.0 Cells_Intensity_Zernike_96.0 Cells_Intensity_Zernike_97.0 Cells_Intensity_Zernike_98.0 Cells_Intensity_Zernike_99.0 Cells_Intensity_Zernike_100.0</div>	Total number of assays tested in: 666. Active in the following assays: <ul style="list-style-type: none"><li>Human H69AR Lung Tumor Cell Growth Inhibition Assay - 86K Screen (AID 598)</li><li>HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors (AID 629)</li><li>Human Endothelial Cell Proliferation Assay in 384-well format (AID 648)</li><li>Human Lung Fibroblast Proliferation Assay (AID 719)</li><li>qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction (AID 1461)</li><li>uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format. (AID 485346)</li><li>HTS Assay for Peg3 Promoter Inhibitors (AID 588405)</li></ul>
Treatment	Score																										
GLI1.WT	-0.71																										
PRKACA.WT.1	-0.65																										
PRKACA.WT.2	-0.62																										
HR23A.Q58L	-0.68																										
Treatment	Score																										
GLI1.WT	0.147																										
PRKACA.WT.1	0.050																										
PRKACA.WT.2	0.054																										
HR23A.Q58L	0.085																										
BRD-K82365559-001-01-6 PubChem CID : 54645938		NA (in 1 replicates)	<div><div>-0.66 ± 0.03</div><table><tr><td>Treatment</td><td>Score</td></tr><tr><td>GLI1.WT</td><td>-0.65</td></tr><tr><td>PRKACA.WT.1</td><td>-0.63</td></tr><tr><td>PRKACA.WT.2</td><td>-0.65</td></tr><tr><td>HR23A.Q58L</td><td>-0.69</td></tr></table></div> <div><div>0.704 ± 0.374</div><table><tr><td>Treatment</td><td>Score</td></tr><tr><td>GLI1.WT</td><td>0.147</td></tr><tr><td>PRKACA.WT.1</td><td>0.050</td></tr><tr><td>PRKACA.WT.2</td><td>0.054</td></tr><tr><td>HR23A.Q58L</td><td>0.085</td></tr></table></div>	Treatment	Score	GLI1.WT	-0.65	PRKACA.WT.1	-0.63	PRKACA.WT.2	-0.65	HR23A.Q58L	-0.69	Treatment	Score	GLI1.WT	0.147	PRKACA.WT.1	0.050	PRKACA.WT.2	0.054	HR23A.Q58L	0.085			<div>Cytoplasm_Intensity_MitotensityEdge_AGP</div> <div>Cells_Intensity_UpperQuartIntensity_DNA Cells_Intensity_MedianIntensity_ER Cells_Intensity_LowerQuartIntensity_RNA Cells_Intensity_IntegratedIntensity_ER</div> <div>Cells_Intensity_IntegratedIntensityEdge_ER Cytoplasm_Intensity_IntegratedIntensityEdge_RNA Nuclei_Texture_Surveillance_AGP_3.0 Cytoplasm_Intensity_UpperQuartIntensity_ER</div> <div>Nuclei_AreaShape_Zernike_3.1 Cells_Intensity_Zernike_0.9 Cytoplasm_AreaShape_Zernike_4.2 Cells_Intensity_Zernike_5.0 Cells_Intensity_Zernike_6.0 Cells_Intensity_Zernike_7.0 Cells_Intensity_Zernike_8.0 Cells_Intensity_Zernike_9.0 Cells_Intensity_Zernike_10.0 Cells_Intensity_Zernike_11.0 Cells_Intensity_Zernike_12.0 Cells_Intensity_Zernike_13.0 Cells_Intensity_Zernike_14.0 Cells_Intensity_Zernike_15.0 Cells_Intensity_Zernike_16.0 Cells_Intensity_Zernike_17.0 Cells_Intensity_Zernike_18.0 Cells_Intensity_Zernike_19.0 Cells_Intensity_Zernike_20.0 Cells_Intensity_Zernike_21.0 Cells_Intensity_Zernike_22.0 Cells_Intensity_Zernike_23.0 Cells_Intensity_Zernike_24.0 Cells_Intensity_Zernike_25.0 Cells_Intensity_Zernike_26.0 Cells_Intensity_Zernike_27.0 Cells_Intensity_Zernike_28.0 Cells_Intensity_Zernike_29.0 Cells_Intensity_Zernike_30.0 Cells_Intensity_Zernike_31.0 Cells_Intensity_Zernike_32.0 Cells_Intensity_Zernike_33.0 Cells_Intensity_Zernike_34.0 Cells_Intensity_Zernike_35.0 Cells_Intensity_Zernike_36.0 Cells_Intensity_Zernike_37.0 Cells_Intensity_Zernike_38.0 Cells_Intensity_Zernike_39.0 Cells_Intensity_Zernike_40.0 Cells_Intensity_Zernike_41.0 Cells_Intensity_Zernike_42.0 Cells_Intensity_Zernike_43.0 Cells_Intensity_Zernike_44.0 Cells_Intensity_Zernike_45.0 Cells_Intensity_Zernike_46.0 Cells_Intensity_Zernike_47.0 Cells_Intensity_Zernike_48.0 Cells_Intensity_Zernike_49.0 Cells_Intensity_Zernike_50.0 Cells_Intensity_Zernike_51.0 Cells_Intensity_Zernike_52.0 Cells_Intensity_Zernike_53.0 Cells_Intensity_Zernike_54.0 Cells_Intensity_Zernike_55.0 Cells_Intensity_Zernike_56.0 Cells_Intensity_Zernike_57.0 Cells_Intensity_Zernike_58.0 Cells_Intensity_Zernike_59.0 Cells_Intensity_Zernike_60.0 Cells_Intensity_Zernike_61.0 Cells_Intensity_Zernike_62.0 Cells_Intensity_Zernike_63.0 Cells_Intensity_Zernike_64.0 Cells_Intensity_Zernike_65.0 Cells_Intensity_Zernike_66.0 Cells_Intensity_Zernike_67.0 Cells_Intensity_Zernike_68.0 Cells_Intensity_Zernike_69.0 Cells_Intensity_Zernike_70.0 Cells_Intensity_Zernike_71.0 Cells_Intensity_Zernike_72.0 Cells_Intensity_Zernike_73.0 Cells_Intensity_Zernike_74.0 Cells_Intensity_Zernike_75.0 Cells_Intensity_Zernike_76.0 Cells_Intensity_Zernike_77.0 Cells_Intensity_Zernike_78.0 Cells_Intensity_Zernike_79.0 Cells_Intensity_Zernike_80.0 Cells_Intensity_Zernike_81.0 Cells_Intensity_Zernike_82.0 Cells_Intensity_Zernike_83.0 Cells_Intensity_Zernike_84.0 Cells_Intensity_Zernike_85.0 Cells_Intensity_Zernike_86.0 Cells_Intensity_Zernike_87.0 Cells_Intensity_Zernike_88.0 Cells_Intensity_Zernike_89.0 Cells_Intensity_Zernike_90.0 Cells_Intensity_Zernike_91.0 Cells_Intensity_Zernike_92.0 Cells_Intensity_Zernike_93.0 Cells_Intensity_Zernike_94.0 Cells_Intensity_Zernike_95.0 Cells_Intensity_Zernike_96.0 Cells_Intensity_Zernike_97.0 Cells_Intensity_Zernike_98.0 Cells_Intensity_Zernike_99.0 Cells_Intensity_Zernike_100.0</div>	Total number of assays tested in: 45. Active in the following assays: <ul style="list-style-type: none"><li>HTS for Bacterial rRNA inhibitors Measured in Microorganism-Based System Using Plate Reader - 7056-01 Inhibitor SinglePoint HTS Activity (AID 720706)</li></ul>
Treatment	Score																										
GLI1.WT	-0.65																										
PRKACA.WT.1	-0.63																										
PRKACA.WT.2	-0.65																										
HR23A.Q58L	-0.69																										
Treatment	Score																										
GLI1.WT	0.147																										
PRKACA.WT.1	0.050																										
PRKACA.WT.2	0.054																										
HR23A.Q58L	0.085																										